Companies / Health Care / Pharmaceuticals
Pfizer stock buybacks
PFE—No share repurchases in the company’s standard SEC financial data for the last twelve months.
Pfizer’s filings haven’t reported share repurchases in standard form since Q4 2023.
Show as table
| Period | Value |
|---|---|
| Q3 '20 | $0 |
| Q4 '20 | $0 |
| Q1 '21 | $0 |
| Q2 '21 | $0 |
| Q3 '21 | $0 |
| Q4 '21 | $0 |
| Q1 '22 | $2B |
| Q2 '22 | $0 |
| Q3 '22 | $0 |
| Q4 '22 | $0 |
| Q1 '23 | $0 |
| Q2 '23 | $0 |
| Q3 '23 | $0 |
| Q4 '23 | $0 |
| Q1 '24 | $0 |
| Q2 '24 | $0 |
| Q3 '24 | $0 |
| Q4 '24 | $0 |
| Q1 '25 | $0 |
| Q2 '25 | $0 |
| Q3 '25 | $0 |
| Q4 '25 | $0 |
| Q1 '26 | $0 |
| Q2 '26 | $0 |
Show as table
| Period | Value |
|---|---|
| Q3 '20 | 5.63B |
| Q4 '20 | 5.66B |
| Q1 '21 | 5.66B |
| Q2 '21 | 5.68B |
| Q3 '21 | 5.72B |
| Q4 '21 | 5.77B |
| Q1 '22 | 5.76B |
| Q2 '22 | 5.71B |
| Q3 '22 | 5.72B |
| Q4 '22 | 5.74B |
| Q1 '23 | 5.73B |
| Q2 '23 | 5.71B |
| Q3 '23 | 5.65B |
| Q4 '23 | 5.75B |
| Q1 '24 | 5.70B |
| Q2 '24 | 5.70B |
| Q3 '24 | 5.71B |
| Q4 '24 | 5.70B |
| Q1 '25 | 5.71B |
| Q2 '25 | 5.71B |
| Q3 '25 | 5.71B |
| Q4 '25 | 5.72B |
| Q1 '26 | 5.73B |
| Q2 '26 | 5.70B |
$0last quarter (Q2 2026)
−$947Mnet of stock compensation ($947M)
−0.1%diluted shares, 1 year
+1.4%diluted shares, 5 years
$9.8Bdividends, 12 months
0%of free cash flow ($11.0B) spent on buybacks
$0raised by issuing stock, 12 months
$3.3Bleft under its authorization as of Dec 31, 2025
Pfizer’s recent filings don’t report repurchases in the standard XBRL fields we read. That usually means it didn’t buy back stock, but some companies report buybacks only in custom fields. Check its latest 10-Q to be sure.
By fiscal year
Questions
- Does Pfizer buy back its stock?
- Pfizer’s filings haven’t reported share repurchases in standard form since Q4 2023.
- How much did Pfizer spend on buybacks in fiscal 2024?
- $0, according to its 10-K for the fiscal year ending Dec 31, 2024.
- Is Pfizer's share count going down?
- Its diluted share count changed +1.4% over five fiscal years and −0.1% over the last year.
- Does Pfizer have a buyback authorization?
- Its filings show $3.3B remaining under its repurchase authorization as of Dec 31, 2025.
Latest filing used: 10-Q for the period ending Jun 28, 2026, filed Aug 4, 2026 · open on SEC.gov